Abstract:Since, after the successful approval of albumin-based nanodrug "Abraxane" by food and drug administration (FDA) in 2005, considerable interests have been gained by protein-based nanoparticles in the field nanomedicine for cancer therapy. In recent years, various protein-based nanodevices have been developed; amid them, serum albumin as an intrinsic constituent of blood with no immunogenicity and toxicity regarded as an ideal tool to cargo and deliver diagnostic and therapeutic modalities to breast cancer cells simultaneously, named as theranostic. Serum albumin-based nanodevices are commonly loaded or conjugated with near infrared (NIR dyes), contrast agents, radionuclides, photosensitizers and organic or inorganic nanoclusters and chemotherapeutic agents. In general, serum albumin nanodevices offer several advantages such as biocompatibility, biodegradability, prolonged blood circulation, escape clearance by macrophages and surface modification with drugs or targeted ligand. Moreover, it can be easily prepared without using any toxic organic solvent or chemical agents. In addition, the nanoscale size of devices also facilitates the deep penetration into tumor tissue. This mini-review embodies general overview of albumin and its properties, tumor targeting mechanism and designed formulations, along with their applications in breast cancer diagnosis and therapy from the recent literature. Finally, the current challenges and future perspective are identified for translating serum albumin-based nanodevices from laboratory to clinical application. Graphical abstract Download : Download high-res image (218KB) Download : Download full-size image

Exploiting Albumin as a Versatile Carrier for Cancer Theranostics

Protein Nanoparticles Directed Cancer Imaging and Therapy

Theranostics System Caged in Human Serum Albumin As a Therapy for Breast Tumors.

Harnessing albumin as a carrier for cancer therapies

Albumin Nanoparticle Encapsulation of Potent Cytotoxic Therapeutics Shows Sustained Drug Release and Alleviates Cancer Drug Toxicity.

Albumin As a "trojan Horse" for Polymeric Nanoconjugate Transendothelial Transport Across Tumor Vasculatures for Improved Cancer Targeting

Multiplexed Imaging with Coordination Nanoparticles for Cancer Diagnosis and Therapy

A Theranostic Photosensitizer-Conjugated Albumin Co-Loading with Resiquimod for Cancer-Targeted Imaging and Robust Photo-Immunotherapy

Aptamer-guided extracellular vesicle theranostics in oncology

The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy

Albumin-based nanodevices for breast cancer diagnosis and therapy

Theranostic nanoparticles with disease-specific administration strategies

Bovine Serum Albumin as a Versatile Platform for Cancer Imaging and Therapy

Drug-Induced Self-Assembly of Modified Albumins as Nano-theranostics for Tumor-Targeted Combination Therapy

Recent Advances in Pretargeted Strategy for Cancer Theranostics.

Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers

Small Fluorescent Albumin Nanoparticles for Targeted Photothermal Therapy Via Albumin-Binding Protein Pathways

Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation

Aptamer–Exosomes for Tumor Theranostics

Nanoparticles for Cancer Diagnosis, Radionuclide Therapy and Theranostics

A Facile, Protein‐Derived Supramolecular Theranostic Strategy for Multimodal‐Imaging‐Guided Photodynamic and Photothermal Immunotherapy In Vivo